前列腺癌术后放疗:常规与大分割方案的比较
研究比较前列腺癌术后大分割放疗(hypoPORT)与常规放疗(coPORT)的急性和晚期毒性及生化控制,共纳入461例患者。hypoPORT组急性≥2级泌尿生殖毒性更常见,6年晚期≥3级泌尿生殖毒性累积发生率更高,但多因素分析校正基线泌尿功能后无显著差异;两组胃肠道毒性无差异。
核心结论
- hypoPORT显示出有前景的早期生化控制,校正基线泌尿功能后未发现其泌尿生殖毒性高于coPORT。
研究设计与样本
- 研究为两机构2005年至2016年连续治疗的前列腺癌术后患者队列,比较hypoPORT与coPORT。
- hypoPORT采用调强放疗,每次2.5 Gy,中位累积剂量65 Gy(范围57.5-70 Gy)。
- coPORT采用每次1.8-2.0 Gy,中位累积剂量66 Gy(范围60-74 Gy)。
- 共纳入461例患者,其中hypoPORT组167例(36%),coPORT组294例(64%)。
- 全组中位随访38.6个月;生化无进展生存(bPFS)在随访≥12个月的患者中计算。
主要发现
- hypoPORT组基线尿失禁显著更差。
- 急性和晚期胃肠道毒性两组无差异。
临床怎么用
- 前列腺癌术后大分割放疗可作为常规分割放疗的替代方案,但需关注急性泌尿生殖毒性。
- 基线尿失禁患者选择大分割放疗时应谨慎评估泌尿生殖毒性风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare acute/late toxicity and biochemical control in contemporaneous prostate cancer patient cohorts treated with hypofractionated postprostatectomy radiation therapy (hypoPORT) or conventional PORT (coPORT). METHODS AND MATERIALS: Consecutive patients treated with intensity modulated hypoPORT (2.5 Gy per fraction, median cumulative dose 65 Gy [range, 57.5-70 Gy]) or coPORT (1.8-2.0 Gy per fraction, median cumulative dose 66 Gy [range, 60-74 Gy]) between 2005 and 2016 at 2 institutions constituted the study cohort. Acute toxicity and cumulative late grade 2 and ≥3 genitourinary (GU) and gastrointestinal (GI) toxicity incidences were calculated for all patients using the Kaplan-Meier method and compared between cohorts. Biochemical progression-free survival (bPFS) was calculated in patients with ≥12 months' follow-up. RESULTS: Median follow-up for all 461 patients was 38.6 months. Of the 461 patients, 167 (36%) received hypoPORT, and 294 (64%) patients received coPORT. The hypoPORT cohort had significantly worse baseline urinary incontinence. Acute grade ≥2 GU toxicity was more common after hypoPORT (22% vs 8%) (P = .0001). Late grade ≥3 GU toxicity cumulative incidence at 6 years was 11% (hypoPORT) and 4% (coPORT) (P = .0081). However, hypoPORT was not associated with late grade ≥2 GU toxicity on multivariate analysis (hazard ratio 1.39, 95% confidence interval 0.86-2.34) (P = .18). There was no difference in acute or late GI toxicity. In the subset of patients with ≥12 month's follow-up (n = 364, median follow-up 52 months), 4-year bPFS was 78% (95% CI 69.4-85.0) after hypoPORT (P = .0038) and 65% (95% CI 57.6-71.1) after coPORT. HypoPORT was not significant for bPFS on multivariate analysis (hazard ratio 0.64, 95% CI 0.41-1.02, P = .059). CONCLUSIONS: HypoPORT shows promising early biochemical control. After controlling for baseline urinary function, hypoPORT was not associated with greater GU toxicity than coPORT. © 2018 Elsevier Inc.
引用
- Tandberg DJ, Oyekunle T, Lee WR, et al. Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559284. doi:10.1016/j.ijrobp.2018.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。